newsfilter
← Earnings
Earnings Releases·

TransMedics Group, Inc. — Third Quarter 2026 Earnings Summary

  • Total revenue rose 41% year-over-year to $203.0 million, driven by 60% growth in service revenue, though net income declined to $17.1 million ($0.46/share) from $24.3 million in the prior-year period due to increased operating expenses.
  • Full-year 2026 revenue guidance was raised to $764-$774 million (including $14 million from PAD Aviation), implying 26%-28% annual growth compared to FY 2025.
  • Strategic progress includes the completion of ENHANCE Heart Part A enrollment, FDA approval for an additional 90 patients, and the award of the first European transplant logistics tender via PAD Aviation.
  • Management highlighted record case volume and strong conviction in the global platform, despite a material weakness in internal controls and risks related to clinical trial outcomes and debt servicing.
Company
TRANSMEDICS GROUP INC
Sector
Healthcare
Industry
Medical Devices